Improved prognosis in children with ovarian cancers following modified VAC (vincristine sulfate, dactinomycin, and cyclophosphamide) chemotherapy.
D000293:Adolescent; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002648:Child; D003520:Cyclophosphamide / Q000627:therapeutic use; D003609:Dactinomycin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004407:Dysgerminoma / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007984:Leydig Cell Tumor / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000601:surgery; D011379:Prognosis; D012075:Remission, Spontaneous; D012707:Sertoli Cell Tumor / Q000188:drug therapy*; D013724:Teratoma / Q000188:drug therapy*; D013997:Time Factors; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D003609:Dactinomycin; D014750:Vincristine; D003520:Cyclophosphamide